NYSEHealth CareMedical - DevicesSnapshot 2026-08-31
Reading SYK? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Stryker grows sales about 8.75% a year as it expands its trauma and orthopedic products. Profit per share stays near $15 in 2026. New products and acquisitions support steady growth. The company manages cybersecurity risks and keeps costs controlled.
Sales growth slows below 8%. Profit per share falls below $14.90. Cybersecurity issues or litigation disrupt operations. New product launches fail to gain traction.
The current price reflects about 11% revenue growth and EPS near $15 for 2026. Our view aligns with these expectations but sees risk if growth or profit weakens.
Breaks if: Adjusted EPS falls below $14.90 in FY26
Stryker aims to maintain adjusted EPS guidance in the range of $14.90 to $15.10 for 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on maintaining strong growth. The current thesis remains intact, supported by solid recent financial results despite some near-term uncertainties.
The market currently prices SYK as justified, with a low fragility tier. Valuation is considered cheap compared to peers, indicating that expectations for future performance are moderate.
Management has consistently delivered on priorities such as organic net sales growth and adjusted EPS growth. Recent results show strong performance, but there is a moderate risk of missing future estimates, which could impact sentiment.
The long-term thesis hinges on the ability to maintain growth amid potential economic challenges and the performance of sector peers. Any cuts to guidance or continued weakness in the jobs report could negatively affect the outlook.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis of strong growth. However, supply chain disruptions threaten the ability to maintain strong organic net sales growth.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Material operational disruption or new cybersecurity incidents occur
Stryker is focused on addressing the cybersecurity incident that affected its IT systems.
Breaks if: YoY revenue growth falls below 8.0% in FY26
Overall, SYK's strong fundamentals and recent performance support a positive view, but caution is warranted due to potential risks. Not investment advice.
